Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections San Francisco, CA March 9-12 2025     HIV Treatment, Long-Acting, New Drug Development, PrEP   Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in The Trio Cohort: increased CD4 - (04/07/25)   Thwarting a protein in the hope of a better quality of life: fostemsavir gp120 aging study - (04/07/25)   Integrase Inhibitor Versus Protease Inhibitor Based Therapy for People with Advanced HIV Disease (LAPTOP) - (04/07/25)   Switch to DTG/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups - (04/07/25)   New HIV Drugs at CROI 2025 - (04/07/25)   A 24-Week Phase II Maintenance Study of TMB-365/TMB-380 Q8W in People With Suppressed HIV-1 Infection - (04/02/25)   A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection - (04/02/25)   Durable Viral Suppression Using Different Definitions in a Ryan White HIV Program Clinic, 2018-2021: overestimated viral suppression - (04/02/25)   Implementation of LA-CAB/RPV in US Settings: A Survey of Front-Line Clinicians - (03/29/25)   What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It? - (03/29/25)   Outcomes in Those Who Discontinued Injectable Cabotegravir/Rilpivirine and Resumed Oral Antiretroviral Therapy - (03/29/25)   Outcomes of LAI-ART for People With Detectable HIV Viremia in the NYC Public Healthcare System - (03/29/25)   The Influence of Racialized Economic Segregation on Unmet HIV prevention Needs in the Real World - (03/29/25)   PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women - (03/29/25)   The Association between PrEP-to-Need Ratio and HIV Incidence Rates in the United States: County-level Analyses From 2012 to 2021 - (03/29/25)   Pre-exposure Prophylaxis Uptake in High Female-to-Male HIV Prevalence Regions in the US - (03/29/25)   Suboptimal laboratory testing of PrEP users - United States, 2022-2023 - (03/29/25)   Qualitative Assessment of Acceptability and Preferences for Injectable and Oral PrEP in PURPOSE 1 - (03/29/25)   Understanding NLRP3 Inflammasome Activation at the Intersection of HIV and Aging - (03/29/25)   US Socioeconomic Disparities and Geographic Variations in HIV Preexposure Prophylaxis Providers - (03/27/25)   No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens - (03/27/25)   Sexual Behaviors Among Gay, Bisexual, and Men who Have Sex with Men (GBMSM) Infected with MPXV in California - (03/27/25)   Long-term Sequelae of Mpox: A Cohort Study in Two Tertiary Centers - (03/27/25)   HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024 - (03/26/25)   Long-Acting Injectable Versus Oral HIV Antiretroviral Therapy for People Experiencing Homelessness - (03/24/25)   LONG-ACTING INJECTABLE ART IN PERSONS WITH HIV-1 VIREMIA IN THE SOUTH: A TOOL TO END THE EPIDEMIC - (03/24/25)   Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic's Long-Acting ART Program (SPLASH) - (03/24/25)   Achievement of Virologic Suppression in the PROMISE-US Study (Ibalizumab) in Subjects Viremic at Baseline - (03/21/25)   Sexual Behaviors Among Gay, Bisexual, and Men who Have Sex with Men (GBMSM) Infected with MPXV in California - (03/21/25)   Long-Acting Cabotegravir and Rilpivirine in Older People with HIV in the GEPPO Cohort - (03/21/25)   Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox - (03/21/25)   Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx - (03/21/25)   DOLPHIN Moms: Pharmacokinetics and HIV suppression with dolutegravir and 1HP or 3HP in pregnancy - (03/21/25)   PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP - (03/19/25)   First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort - (03/19/25)   Why Do People With HIV Stop Long-Acting Injectable Cabotegravir-Rilpivirine and What Happens? - (03/19/25)   Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention - (03/17/25)   Injectable Cabotegravir PrEP Discontinuations at a Peer Specialist-Led Program in Washington, D.C. - (03/17/25)   Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in PWH With Adherence Challenges - (03/17/25)   Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083 - (03/17/25)   Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084 - (03/17/25)   Diagnosis, Resistance, and ART Outcomes after HIV Acquisition on CAB-LA PrEP in Routine Care in U.S. - (03/17/25)   RESPONSE TO HIV TREATMENT AFTER LONG-ACTING CABOTEGRAVIR PRE-EXPOSURE PROPHYLAXIS IN HPTN 083 - (03/17/25)   Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/14/25)   HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial - (03/13/25)   Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - (03/13/25)   ViiV HEALTHCARE'S INVESTIGATIONAL BROADLY NEUTRALISING ANTIBODY - N6LS - SUCCESSFULLY MAINTAINS VIRAL SUPPRESSION IN LONG-ACTING TREATMENT OF HIV - (03/13/25)   VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - (03/13/25)   Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1 - (03/13/25)   Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: a Blinded Phase 3 Study in Adults with HIV-1 - (03/13/25)   Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay - (03/13/25)   Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES):Week 96 Result - (03/13/25)   Long-acting Cabotegravir PrEP Uptake and Persistence in a Large U.S. Healthcare System - (03/13/25)   Preliminary Efficacy for HPTN 094: 26-week RCT of Integrated Strategies for People Who Inject Drugs - (03/13/25)   ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations - (03/13/25)   Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/13/25)   Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1 - (03/12/25)   5'Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART (NSV) - (03/12/25)   Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor - (03/12/25)   Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor - (03/12/25)   Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study published - (03/12/25)   ViiV HEALTHCARE SHOWCASES LEADERSHIP IN LONG-ACTING INJECTABLES INNOVATION AT CROI 2025 WITH DATA ON THIRD-GENERATION INTEGRASE INHIBITOR (INSTI) AND HIGHLY POTENT CAPSID INHIBITOR AGAINST HIV-1 - (03/12/25)   First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet - (03/12/25)   Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 26 Primary Outcome - (03/12/25)   Update on Merck's Late-Stage HIV Pipeline - (03/11/25)   Update on Update on the Long-Acting HIV Treatment and Prevention Pipeline - (03/11/25)   MK-8527 PK/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis - (03/11/25)   Current status of LA/ER Cabotegravir (CAB) and Rilpivirine including pipeline report - (03/11/25)   In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral INSTI in Clinical Development - (03/11/25)   Modeling Accurately Predicts Efficacious Islatravir QW Dose with no Lymphocyte and CD4 Changes - (03/11/25)   Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir - (03/11/25)   Bictegravir + Lenacapavir: Baseline and Week 48 Resistance Analyses in ARTISTRY-1 Phase 2 - (03/11/25)   Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks - (03/11/25)   Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort - (03/11/25)   Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort - (03/11/25)   Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort - (03/11/25)   Aging, Comorbidities: brain, Epigenetic, heart-REPRIEVE, Frailty, Semaglutide, diabetes   10-Minute Targeted Geriatric Assessment identifies vulnerable and frail older persons with HIV - (04/10/25)   Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in The Trio Cohort: increased CD4 - (04/07/25)   Thwarting a protein in the hope of a better quality of life: fostemsavir gp120 aging study - (04/07/25)   Cardiometabolic Effects of Semaglutide in People With HIV: The Slim Liver Study - (04/07/25)   Racial Inequity in Initiation of Semaglutide Therapy Among People With HIV in Care Across the US - (04/07/25)   Patterns of Social and Biological Risk Factors in People with HIV and Risk of Cardiovascular Disease - (04/07/25)   People with HIV at high cardiovascular risk were undertreated with statins - (04/07/25)   Impact of Switching from DTG/3TC to BIC/FTC/TAF on Weight, Cholesterol and Inflammation in HIV - (04/07/25)   Impact of ART Simplification with Dolutegravir and Lamivudine on the HIV Reservoirs - (04/07/25)   Statin Effect Heterogeneity on Plaque Volume & Composition in the REPRIEVE Mechanistic Substudy: non calcified plaque reduction - (04/07/25)   Effect of 12-month Switch to Dual cART on HIV reservoir, T-cell homeostasis, Gut and Mitochondrial Damage - (04/07/25)   CHANGE IN CARDIOMETABOLIC RISK MARKERS FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (04/01/25)   Senescence-Associated Secretory Phenotype Biomarker Profiles of Aging-Related Outcomes in PWH - (04/01/25)   Characteristics and Needs of Lifetime Survivors with HIV in the United States, 2015-2022 - (03/29/25)   Disparities in hospitalization among people in the HIV Outpatient Study, United States 2008-2022: aging, comorbities & racial disparities - (03/29/25)   Understanding NLRP3 Inflammasome Activation at the Intersection of HIV and Aging - (03/28/25)   LOW-DENSITY LIPOPROTEIN CHANGES IN PEOPLE WITH HIV INITIATING STATINS FOR PRIMARY PREVENTION - (03/27/25)   Plasma Inflammation is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV - (03/24/25)   Preliminary Analysis of Longitudinal Synaptic Density Change in Virally Suppressed People with HIV - (03/24/25)   Falls Associated with High Medication Regimen Complexity in People with HIV - (03/24/25)   Interaction Between Age, Brain Volume, and HIV Status in Predicting Cognition; Legacy Affect - (03/24/25)   Association of delayed HIV diagnosis or ART initiation (CD4 nadir) with risk of age-associated dementia - (03/24/25)   The Effects of Depression and Anti-Depressants on Cognition and Brain Volume in PWH and PWoH - (03/24/25)   Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies in CNICS (Centers for AIDS Research Network of Integrated Clinical Systems) - (03/24/25)   Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV - (03/24/25)   Analyzing Neuroanatomical Heterogeneity in HIV-Associated Cognitive Impairment - (03/24/25)   HIV Transcripts in Blood May Identify Patients at Lower Risk of Brain Injury in Cure Research (E06) CNS HIV Reservoirs - (03/24/25)   HIV-infected microglia drive transcriptional and metabolic changes in complex human brain organoids - (03/24/25)   Cannabis Use is Associated with Reduced Brain Integrity in Persons with HIV - (03/24/25)   Brain Volume Normalization After 96 weeks of ART Started During Acute HIV Infection - (03/24/25)   Spinal cord as a distinct site of HIV persistence and dispersal in the Brain - (03/24/25)   Neuroinflammation Associated With Levels of HIV DNA in the Frontal Cortex of Virally Suppressed PWH - (03/24/25)   UNMASKING THE INDEPENDENT ROLE OF CSF HIVRNA DYNAMICS BY SINGLE COPY ASSAY IN NEUROBIOTYPES - (03/24/25)   Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART - (03/24/25)   Weight Change on F/TAF Versus Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials - (03/24/25)   Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance - (03/22/25)   Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection - (03/22/25)   Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance - (03/22/25)   Incidence and Risk Factors for Neurocognitive Disorders Among Persons with HIV in Washington, DC - (03/22/25)   Epigenetic biomarkers of biological age as predictors of AIDS, non-AIDS events and diseases characteristics of aging in persons with HIV - (03/22/25)   Long-term Outcomes of Young Adults with Perinatal HIV Infection in the U.S. - (03/22/25)   Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects - (03/22/25)   Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy - (03/22/25)   HIV and Antiretrovirals have unique in vivo effects on insulin resistance in HIV - (03/22/25)   Highly durable seroprotection with HepB-CpG vaccine in people with HIV (PWH): ACTG A5379 (BEeHIVe) - (03/22/25)   Menopause is Associated with Faster Increases in Insulin Resistance in Women with HIV - (03/22/25)   Obstructive Sleep Apnea and Prevalent Diabetes Mellitus in the Multicenter AIDS Cohort Study - (03/22/25)   Prognostic Factors of Physical Function Decline in the PREPARE Study - (03/21/25)   Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda - (03/21/25)   Major Improvement in Age-Related Health Outcomes in People Living with HIV: A 18-Year Cohort Study - (03/21/25)   Relationship of ST-2, Epicardial Fat and Coronary Calcium with Diastolic Dysfunction in Older PWH - (03/21/25)   D-Drugs and Heart Failure - (03/21/25)   Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies in CNICS (Centers for AIDS Research Network of Integrated Clinical Systems) - (03/21/25)   Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy: PWH & heart failure have low scores indicating suboptimal care and intensity of heart failure treatment. - (03/21/25)   Decreased adipose tissue gene expression after a 48-week switch from an INSTI regimen to TDF/3TC/DOR - (03/21/25)   Heart Failure Risk and Events in People with HIV in the REPRIEVE Trial - (03/21/25)   No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People with HIV - (03/21/25)   Low-level HIV viremia increases immunosuppressive markers elevating cancer and CVD risk in INSTI era - (03/20/25)   Trends in Common Cancer Diagnoses Among People with HIV in North America from 2006-2020 - (03/20/25)   The 10-year Prevalence [doubling] of Hearing Loss and Dementia Among People with HIV in the United States - (03/20/25)   Falls Associated with High Medication Regimen Complexity in People with HIV - (03/20/25)   Frailty and All-Cause Mortality among People with HIV Engaged in Clinical Care in the United States - (03/20/25)   Epigenetic Age Acceleration and Mortality among Persons who Inject Drugs with Poorly Controlled HIV, median age 48 - (03/20/25)   PROJECTING CHANGES IN DEMOGRAPHICS AND CAUSES OF DEATH AMONG PEOPLE WITH HIV IN WESTERN EUROPE TO 2050: A MATHEMATICAL MODELLING STUDY - (03/20/25)   Reducing HIV Diagnoses and Mortality Rate Further Increase Aging Resource Needs for PWH Into 2040 - (03/20/25)   Mortality in the HIV Outpatient Study (HOPS), Trends and Risks 2007-2022 - (03/20/25)   Psychotic Disorders in Young Adults with Perinatally-Acquired HIV: a Multicentre UK Study - (03/20/25)   Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study - (03/20/25)   Spinal cord as a distinct site of HIV persistence and dispersal in the Brain - (03/20/25)   Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART - (03/20/25)   The 10-year Prevalence of Hearing Loss and Dementia Among People with HIV in the United States - (03/19/25)   Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study - (03/19/25)   Trends in incident HCV infection among PWH engaged in care in the US-1995-2023: 2-fold increase in MSM; high stable rates among PWID & MSM-WID - (03/17/25)   Plaque, Inflammation, Subclinical Myocardial Injury and MACE in the REPRIEVE Mechanistic Substudy - (03/17/25)   BMI IS A POOR SURROGATE FOR EXCESS VISCERAL ADIPOSITY AND CARDIOVASCULAR RISK IN PEOPLE WITH HIV (PWH) - (03/17/25)   Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy - (03/17/25)   Epigenetic biomarkers of biological age as predictors of AIDS, non-AIDS events and diseases characteristics of aging in persons with HIV - (03/17/25)   Metformin for Reversal of Accelerated Biological Aging in Persons With HIV: A Pilot Clinical Trial - (03/17/25)   Epigenetic Age Acceleration and CD4/CD8 Ratio in People With Well-Controlled HIV Infection - (03/17/25)   EPIGENETIC AGE PREDICTORS OF SEMAGLUTIDE- RELATED LIVER FAT CHANGES IN PEOPLE WITH HIV - (03/17/25)   Systemic Immune-Inflammation Index Links to Slower Psychomotor Speed in Older People with HIV - (03/17/25)   Trends in incident HCV infection among PWH engaged in care in the US-1995-2023: 2-fold increase in MSM; high stable rates among PWID & MSM-WID - (03/17/25)   Efficacy and Inflammatory Markers After 144 Weeks of Switch to DTG/3TC in a Randomized Trial - (03/17/25)   Body Composition Changes in People With HIV Switching to DTG/3TC or BIC/FTC/TAF - (03/17/25)   Switching to DTG/3TC vs. BIC/FTC/TAF and Steatotic Liver Disease: A Sub-study PASODOBLE Trial - (03/17/25)   Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV - (03/14/25)   Mitochondrial DNA Variation and Physical Function among Men with and without HIV - (03/12/25)   Risk of Incident Hypertension with Common Antiretroviral Agent Combinations in the OPERA Cohort - (03/11/25)   Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials - (03/11/25)   No Increased Risk for Hypertension with CAB-LA Compared to TDF/FTC for PrEP: Results from HPTN 084 - (03/11/25)   DoxyPEP   Impact of Doxycycline as STI Postexposure Prophylaxis on the Gut Microbiome and Antimicrobial Resistance Gene Expression - (03/26/25)   PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP - (03/17/25)   DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC...."early uptake of DoxyPEP was minimal, yet a majority of PWH were DoxyPEP eligible" - (03/15/25)   High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation - (03/15/25)   The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco; Low Starts, Adherence - (03/15/25)   Young Black Sexually Minoritized Men Living with HIV, Substance Use, and Syphilis Want Doxy-PEP - (03/11/25)   Characteristics of Breakthrough Chlamydia Cases among Cisgender Women Assigned to Doxycycline Postexposure Prophylaxis - (03/11/25)   Post-Exposure Prophylaxis With Doxycycline (DoxyPEP) in a Cohort of High-Risk MSM: The PRIDOX Study - (03/11/25)   Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Sexual Health Clinic, 2023-2024 - (03/11/25)   Hepatitis, Liver   ALLIANCE Open-Label Extension: Switch to B/F/TAF in People With Both HIV-1 and HBV - (03/24/25)   HIV-1 Resistance Analysis of Treatment-Naïve People With HIV and HBV Receiving B/F/TAF or DTG + F/TDF - (03/24/25)   Preclinical Pharmacokinetic Assessment of a Long-acting Solid Injectable for Hepatitis C Virus - (03/22/25)   Highly durable seroprotection with HepB-CpG vaccine in people with HIV (PWH): ACTG A5379 (BEeHIVe) - (03/22/25)   Direct Acting Antiviral Initiation among People with HIV and HCV in North America: Factors Driving the Treatment Gap - (03/22/25)   Comorbidities among Medicaid Enrollees with Chronic Hepatitis C, 2016-2020 - (03/20/25)   Lipidomics of metabolic dysfunction-associated steatotic liver disease post-HCV eradication in PWH - (03/20/25)   Liver Steatosis progression with Integrase Inhibitors in HIV Adults in Low-/Middle-Income Countries - (03/20/25)   Semaglutide Improves Steatohepatitis in People With HIV: The SLIM LIVER Study - (03/20/25)   Evaluation of different non-invasive models in assessing lean MAFLD among PLWH: High rates of Lean MAFLD - (03/20/25)   Effects of Semaglutide on Gut Microbiota in People With HIV: The SLIM LIVER Study - (03/20/25)   Determinants of Steatotic Liver Disease Among People with HIV in Europe and Australia - (03/20/25)   HBsAg SEROCLEARANCE IN HIV AND HBV-COINFECTED PATIENTS IN THE ERA OF TENOFOVIR-CONTAINING THERAPY - (03/20/25)   Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir - (03/20/25)   HBV Reactivation Post-switch to HBV-inactive ART: A Scoping Review - (03/20/25)   Incidence and Impact of Hepatic Steatosis in People with HIV: Insights from the NA-ACCORD Cohort - (03/17/25)   Safety and Efficacy of Glecaprevir/Pibrentasvir for 8 Weeks for Treatment of Acute Hepatitis C Virus Infection in People Living with HIV - (03/11/25)   Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure - (03/11/25)   "HIV Cure", Viral Control   Time to Viremia and Frequency of Post-Treatment Control Among 382 "Placebo-Treated" ATI Participants - (03/22/25)   Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription - (03/22/25)   Therapeutic HIV Vaccine: T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV - (03/20/25)   T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV - (03/17/25)   Trosunilimab Safety, Pharmacokinetics and Pharmacodynamics in Healthy People and People With HIV-1 - (03/17/25)   Sustained HIV Remission Despite Transient Rebound Viremia After a CCR5Δ/ΔStem Cell Transplant - (03/17/25)   HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant from CCR5Δ32/Δ32 Sibling Donor - (03/17/25)   Trends in incident HCV infection among PWH engaged in care in the US-1995-2023: 2-fold increase in MSM; high stable rates among PWID & MSM-WID - (03/17/25)   AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques - (03/13/25)   Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - (03/13/25)   The RIO trial: A Randomised Placebo-Controlled Study of 2 LS-bNAbs (3BNC-117-LS & 10-1074-LS) in People Treated in Early HIV - (03/12/25)   Evaluation of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With HIV-1 During Analytical Treatment Interruption - (03/12/25)   The Barrier to HIV-1 Escape from Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates - (03/11/25)